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Abstract
Tumor budding is a promising and cost-effective biomarker with strong prognostic value in colorectal cancer. However,
challenges related to interobserver variability persist. Such variability may be reduced by immunohistochemistry and
computer-aided tumor bud selection. Development of computer algorithms for this purpose requires unequivocal
examples of individual tumor buds. As such, we undertook a large-scale, international, and digital observer study on
individual tumor bud assessment. From a pool of 46 colorectal cancer cases with tumor budding, 3000 tumor bud
candidates were selected, largely based on digital image analysis algorithms. For each candidate bud, an image patch
(size 256 × 256 µm) was extracted from a pan cytokeratin-stained whole-slide image. Members of an International Tumor
Budding Consortium (n= 7) were asked to categorize each candidate as either (1) tumor bud, (2) poorly differentiated
cluster, or (3) neither, based on current deﬁnitions. Agreement was assessed with Cohen’s and Fleiss Kappa statistics.
Fleiss Kappa showed moderate overall agreement between observers (0.42 and 0.51), while Cohen’s Kappas ranged
from 0.25 to 0.63. Complete agreement by all seven observers was present for only 34% of the 3000 tumor bud
candidates, while 59% of the candidates were agreed on by at least ﬁve of the seven observers. Despite reports of
moderate-to-substantial agreement with respect to tumor budding grade, agreement with respect to individual pan
cytokeratin-stained tumor buds is moderate at most. A machine learning approach may prove especially useful for a more
robust assessment of individual tumor buds.
Introduction
Tumor budding, deﬁned as the presence of single cells or
small clusters of up to four tumor cells, may be seen at the
invasive front of colorectal cancer and other tumor types
[1]. Tumor buds (TB) are detached (epithelial) tumor cells
that, in close interaction with their microenvironment,
transform at least partially into a mesenchymal stem-like
phenotype. In the process, TB lose some of their epithelial
characteristics and acquire features that are correlated with
increased cell motility [2]. TB are morphologically and
biologically related to poorly differentiated clusters
(PDC’s), which represent larger tumor cell clusters (ﬁve or
more cells without gland formation), and which are also
located at the tumor invasive front [3].
The clinical signiﬁcance of the extent of TB as an
independent risk factor for adverse outcomes in colorectal
cancer (CRC) is now well established [4–8]. However, until
recently the reporting of tumor budding in routine practice
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was held back by a lack of internationally accepted criteria
and methodology for its assessment. The recent publication
of evidence-based recommendations for TB assessment,
formulated during the International Tumor Budding Con-
sensus Conference (ITBCC, 2016), removed an important
barrier to the wider reporting of TB [1].
As with all adverse histologic features (and especially
those requiring quantitation), interobserver agreement of
tumor budding is suboptimal. The degree of interobserver
variability may be inﬂuenced by the type of stain used
(H&E vs. immunohistochemistry), the number of output
categories, cut-off values, and experience/expertise of
the observers [9–11]. Although reported concordance
between observers has generally been within acceptable
limits, ongoing concerns regarding interobserver varia-
bility have continued to hamper clinical adoption. Inter-
observer variability in TB assessment may be greatly
reduced by computer-aided detection systems. A class of
algorithms based on deep learning and capable of recog-
nizing complex tissue structures and patterns is emerging
as a promising tool in medical imaging and digital
pathology, matching, and in some cases surpassing human
performance [12–14]. A requirement for successful
development of such supervised deep learning algorithms
is the availability of a sufﬁcient amount of correctly
labeled input data. As such, its application to TB assess-
ment requires a large number of images containing TB
which have been conﬁrmed by (a panel of) experienced
pathologists.
We have previously assessed tumor budding [15] in
digital images from preselected hotspot locations, both on
H&E and in cytokeratin 8–18 (CK) stained slides with the
purpose of identifying TB for training computer algo-
rithms. Moderate Kappa scores were found between two
pathologists in scoring tumor budding grade, and notably
few individual buds were annotated by both pathologists
(H&E 38% and CK 54% of the total annotated TB),
indicating considerable interobserver variation in identi-
fying individual TB.
In the present study, we aim to establish the level of
agreement among expert pathologists when assessing a
series of 3000 individual tumor bud candidates in digital
images of CK stained slides. Our study differs from other
observer studies, which have largely focused on overall
tumor budding grade rather than individual TB. Digitized
images of 3000 TB-candidates were submitted to an
international panel of experts, with the request to deter-
mine per candidate status as follows: TB, PDC, or neither.
We have chosen to derive these TB/PDC candidates
mainly from pan-CK stained tissue. For comparison pur-
poses 150 of the 3000 TB-candidates were also offered for
evaluation in ITBCC preferred H&E stained version
separately.
Material and methods
Materials
From three centers, a total of 46 CRC patients were selected,
in which routine diagnostic assessment had revealed the
presence of TB. Per patient, one parafﬁn-embedded tissue
block was included. Two slides were stained with AE1–AE3
immunohistochemistry at the Dublin University Hospital, ﬁve
slides were stained with AE1–AE3 immunohistochemistry at
Bern University Labs. The remaining 39 slides were stained
with H&E, digitally captured (producing whole slide images;
WSI), subsequently destained, restained with CK8-18
immunohistochemistry, and scanned again at the Radboud
UMC in Nijmegen (procedure described by van den Brand
et al. [16]). All slides were scanned with a Pannoramic P250
Flash II scanner (3D-Histech, Hungary) using a 40× objective
lens (yielding specimen level pixel-size of 0.24 × 0.24 μm).
As only fully anonymized archival tissue was used in this
study, the need for ethical approval was waived by the
institutional review board of Radboud UMC.
The set of 3000 TB-candidates was comprised of 800 TB-
candidates, taken from a previous study [15]. The remaining
2200 TB-candidates were selected as follows. One pathologist
marked hotspot regions (measuring 0.785mm2) in the
immunohistochemistry stained slides. Next, an image analysis
algorithm was used to automatically identify individual bud
candidates. The algorithm performed a color deconvolution
[17] to isolate DAB positive image pixels, which were
grouped to form binary objects. Only objects with a surface
area between 25 and 5000 μm2 were retained, to remove small
artifacts and larger clusters of tumor cells. Candidates were
visually checked by an expert and obvious artifacts were
omitted. From the remaining objects, 1900 TB-candidates
with surface area <1000 μm2 were taken (mostly representing
TB) and another 300 candidates with surface area >1000 μm2
(containing mainly PDC’s) were randomly chosen, to ensure
sufﬁcient presence of TB. The set of 3000 candidates was
randomly split into two groups of 1500 cases.
Restaining of the slides allowed us to select identical
objects in both H&E and CK immunohistochemistry stains.
A part of the 3000 candidates was traced based on their
immunohistochemistry image coordinates into the equiva-
lent images in H&E stain. A total of 150 TB-candidates
were sampled in H&E, selecting these randomly from dif-
ferent groups (i.e., TB, PDC, neither) in proportion to the
number of objects per group.
Method
Eleven pathologists from seven different institutions across
seven different countries, all with expertise in the ﬁeld of
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tumor budding, were invited to participate in this study.
Pathologists were asked to evaluate two study sets each
including 1500 TB/PDC candidates in immunohistochem-
istry and, 2 months later, a set of 150 TB/PDC candidates
on H&E according to ITBCC guidelines and best practice,
including the rule to regard a visible presence of the nucleus
as a requirement. Observers were asked to designate the
candidates into one of three categories, namely (1) TB, (2)
PDC, or (3) neither (no TB, no PDC). The “gold standard”
status of an object was deﬁned using a voting rule of 70% or
more: the label is assigned if at least 5 out of 7 and 8 out of
11 pathologists agree in immunohistochemistry and H&E,
respectively. To enable simultaneous execution of these
tasks by different pathologists from the various work
locations, a web-based platform was used. Through this
platform, patches of 0.25 × 0.25 mm were shown, based on
the center of mass (CoM) of each candidate. To clearly
mark the object of interest, a square with a ﬁxed size of
0.03 mm2 was added, based again on its CoM. An example
is shown in Fig. 1.
Fleiss Kappa and Cohen’s Kappa were used to calcu-
late agreement between multiple observers and different
combinations of two observers (one vs. one) respectively.
For the Kappa scores we used the terms formulated by
Landis and Koch [18], i.e., <0.2 poor, 0.21–0.40
fair, 0.40–0.60 moderate, 0.61–0.80 good, and >0.80
very good.
Results
Immunohistochemistry results were obtained from nine
pathologists, ﬁve of whom scored both sets of 1500 TB/
PDC candidates. The remaining four pathologists scored
either the ﬁrst or the second 1500 candidates. As a result,
7 scores were obtained per TB/PDC object.
Of the 3000 TB/PDC candidates, 612, 15, and 386 cases
were unanimously classiﬁed as TB positive, PDC positive, or
neither, respectively. Based on the previously agreed 70%-
majority vote, we came to a further deﬁnite classiﬁcation for
1765 candidates (1010 TB, 52 PDC, and 703 neither). For
the remaining 1235 candidates, no consensus could be
achieved. An overview of all scores can be found in Table 1;
examples of every category can be found in Fig. 2.
Of the 2 × 1500 immunohistochemistry candidates, on
average 803 (±194), 67 (±28), and 630 (±201) were clas-
siﬁed as TB, PDC, or neither in Group 1. In Group 2, 758
(±118), 111 (±31), and 631 (±143) candidates were labeled
as TB, PDC, or neither (Table 2). Individual scores are
shown in Fig. 3.
Fleiss Kappa was calculated for the ﬁrst 1500 TB-
candidates (classiﬁcation result Group 1) and the second
1500 TB-candidates (classiﬁcation result Group 2) sepa-
rately. With values of 0.42 for the ﬁrst group and 0.51 for
the second group, assessment in both groups showed
moderate agreement.
One-versus-one observer agreement numbers (Cohen's
Kappa) are shown per group in Fig. 4. In the ﬁrst group
these scores vary between 0.24 and 0.60, in the second
group they range from 0.36 to 0.65. In the second observer
group, the 2nd, 3rd, 4th, and 5th observer achieved a higher
agreement score compared with each other. This is also
reﬂected in the lower standard deviation numbers of the
second group compared with the ﬁrst one.
A series of 150 TB/PDC candidates on H&E stained
sections was assessed by 11 observers. A Fleiss Kappa of
0.49 was achieved on this subset. The Cohen Kappa num-
bers ranged from 0.07 to 0.782 (Fig. 5). Of the 150 H&E
candidates on average 54 (±18), 13 (±2), and 84 (±19), were
classiﬁed as TB, PDC, or neither. Individual scores can be
found in Fig. 6.
Fig. 1 Example of TB-candidate in IHC and re-stained H&E.
Example of TB-candidate in a immunohistochemistry, and b restained
H&E.
Table 1 Number of objects, classiﬁed as TB, PDC, or neither by all, majority, or minority (no agreement) per candidate group (3000 IHC, 150
H&E, and 150 IHC).
Uniform 70% majority No agreement
(all classes)
Bud PDC Neither Bud PDC Neither
IHC (3000 objects) 612 (20.40%) 15 (0.50%) 386 (12.87%) 398 (13.27%) 37 (1.23%) 317 (10.57%) 1235 (41.17%)
H&E (150 objects) 8 (5.33%) 1 (0.67%) 13 (8.67%) 31 (20.67%) 10 (6.67%) 68 (45.33%) 19 (12.67%)
IHC reference group (150 objects) 26 (17.33%) 5 (3.33%) 25 (16.00%) 25 (16.67%) 7 (4.67%) 24 (16.00%) 38 (25.33%)
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Fig. 2 Examples of TB-candidates with manual scores. Examples
of TB-candidates a, b uniform selected as bud, c, d majority vote bud,
e, f uniform PDC, g, h majority vote PDC, i, j uniform neither,
k, l majority vote neither. m–p no agreement was reached. Legend of
colors: blue—bud, orange—PDC, gray—neither.
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Table 1 shows that 8, 1, and 13 cases were unanimously
classiﬁed as TB positive, PDC positive, and neither
respectively. Based on the majority vote we counted 39 TB,
11 PDC, and 81 neither. On 19 cases no agreement could be
reached.
The number of “no agreement” objects was therefore
decreased in H&E compared with the immunohistochemistry
reference group. Numbers of PDC remained virtually
unchanged, but the number of objects, classiﬁed as TB by at
least 5 of the 7 observers (Uniform+Majority), decreased on
balance with higher numbers of neither class (25+ 24 versus
Fig. 3 TB, PDC and neither scores in the 2 × 1500 immunohistochemistry dataset per observer.
Table 2 Averaged number of objects (with std. dev.) per observer
group.
Per observer group × dataset: Mean number (std. dev.) of TB, PDC, or
neither
Bud PDC Neither
IHC—Group 1 (1500 objects) 803 (193) 67 (28) 630 (201)
IHC—Group 2 (1500 objects) 758 (118) 111 (30) 631 (142)
H&E (150 objects) 54 (18) 13 (2) 84 (19)
IHC reference group (150 objects) 70 (14) 12 (2) 68 (14)
Fig. 4 One-versus-one Cohen Kappa scores per observer of left group 1 and right group 2.
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13+ 68 objects). Table 2 also shows that the average number
of PDCs in the H&E group almost corresponds to the average
number of PDCs in the immunohistochemistry reference
group. Example cases can be found in Fig. 7.
Discussion
In contrast to previous studies, we assessed observer
variability in scoring individual TB, rather than the overall
budding. This approach prevented pathologists from
unsubconsciously taking the tumor grade and differentiation
grade into account when assessing individual TB. Accurate
identiﬁcation of individual TB is critical for subsequent
development of artiﬁcial intelligence models which can
automate this task, thereby potentially reducing observer
bias. We found that the agreement between pathologists for
scoring buds in immunohistochemistry was only moderate,
which was slightly improved if buds were identiﬁed in
H&E. Only one in three of the 3000 immunohistochemi-
cally stained candidates was uniformly classiﬁed as either
TB, PDC, or neither by unanimity or majority vote. No
agreement was reached on average for four out of ten
candidates. Since interobserver variability in the assessment
of individual TB can result in variability in tumor budding
grades, it is of interest to investigate the cause(s) of such
variability.
In the interpretation and assessment of structures in
immunohistochemistry, TB/PDCs can be mistaken for
other cytokeratin-positive objects. These objects can be
partially described as remnants, parts of epithelium that is
at some stage of degradation. Various studies provide
examples of this. Mitrovic et al. [19] cites fragmentation of
neoplastic glandular structures as a possible cause of
misclassiﬁcation. In line with this, Kai et al. [20] call the
presence of “pseudo buds” an unexpected pitfall in the
assessment of TB in immunohistochemistry, especially in
cases with severe inﬂammation. They consider pseudo
buds to be comprised of fragmented epithelium, destroyed
by inﬂammatory cells. Koelzer et al. [9] note that the
assessment of TB in immunohistochemistry can be
complicated by the presence of cytokeratin-positive
microvesicles and membrane fragments. Although notFig. 5 Cohen Kappa scores per observer for the 150 H&E cases.
Fig. 6 TB, PDC, and neither scores in the 150 H&E dataset per observer with the addition of scores of the identical objects in immunohis-
tochemistry staining.
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mentioned, degenerating or apoptotic cells are also part of
this CK positive group.
In contrast, Shinto et al. [21] researched the morphology,
conﬁguration, and role of small nonnucleated cytoplasmic
fragments (minimum diameter 2 μm) often detected around
TB. The authors observe that some cytoplasmic fragments
are clearly connected with budding foci, suggesting that
they represent dendritic cell processes, rather than isolated
cell fragments. They, therefore, have renamed them cyto-
plasmic pseudo fragments.
As we used a minimum area of 25 μm2 for the computer-
aided preselection of TB-candidates, cytoplasmic pseudo
fragments were removed a priori from the candidate group.
As a consequence, interobserver variability can only be
associated with the ﬁrst-mentioned objects in this study.
Since no deﬁnite cause could be found in the candidates for
whom no agreement was reached, further research will have
to show whether/to what extent each of them actually
contributes to interobserver disagreement.
Clear presence of a cell nucleus is an important criterion
for TB/PDC as it allows observers to distinguish TB/PDC
from aforementioned CK positives.
Although CK staining helps in the ﬁrst phase of detection
of the (malignant) epithelium, e.g., the hotspot selection,
slight overstaining can be counterproductive because
informative variations in intensity that help the interpreta-
tion of morphological structures can be lost for the human
observer. It is therefore possible that part of the disagree-
ment in immunohistochemistry can be traced to poor visi-
bility of the nuclei in this study, where observers did not
have much opportunity to fall back on relevant information
from the context, i.e., nearby gland fully intact or not,
position of the candidate relative to the gland, but also
frame of reference for estimating area/size of the candidate.
As is well known, the human eye is quite poor at judging
minor variations in intensity, but computers are especially
good at assessing ﬁner shades of intensity. A number of
researchers have now entered the ﬁeld of automatic
Fig. 7 Score shifted examples of restained TB-candidates. a, b Shift in the agreement from uniform bud vote in immunohistochemistry to no
agreement in H&E, c shift from majority vote on tumor bud in immunohistochemistry to uniform neither assessment in H&E.
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detection of TB in IHC stained slides. In a recent article,
Bergler et al. [22] present a hybrid method. In a ﬁrst phase
detection step, TB-candidates are generated using classical
image processing methods, whereby the segmentation of
pan-CK positive objects primarily is performed on color
information or signal intensity thresholds and information
on size. A second operation then is added to this phase,
which is aimed at reducing the number of false positives
and carried out with the help of deep learning-based algo-
rithms. Weis et al. [23] follow a similar protocol for
immunohistochemistry stained TMA cores. Both authors
show promising results but need further validation before
implementation in daily clinical routine.
When H&E sections were presented, a group of 11
observers achieved the same moderate overall performance
on the assessment of 150 TB/PDC candidates. The inter-
observer agreement on H&E is similar to the level of
agreement on immunohistochemistry. We did see a shift in
the classiﬁcations, however, there was a decrease in can-
didates classiﬁed as TB and an increase in candidates
classiﬁed as neither. The variability in classiﬁcation of TB’s
on H&E—other than in immunohistochemistry—may be
related to challenges in differentiating TB from inﬂamma-
tory cells (lymphocytes, histiocytes, and macrophages) and
stromal cells, as activated ﬁbroblasts [19]. Based on this
observation, we hypothesize that interobserver variability
may be less attributable to TB composed of clusters of 2–4
cells than to individual cell TB. As the number of cells of
the candidates was not registered, we could not test this
hypothesis in this study. It is worth considering this in
future investigations.
Relevant morphological cell characteristics are better
preserved in H&E, but TB detection is then more time-
consuming. Furthermore, there is a greater chance of
TB’s being overlooked compared to IHC, where the main
issue is “overcall” due to the presence of TB mimics.
Nevertheless, based on the results of this study, there is
no reason to deviate from the ITBCC preference for H&E
staining at this time. It should be noted, however, that
only a relatively small number of TB-candidates were
classiﬁed in H&E sections.
In conclusion, we have shown that the assessment of
individual TB-candidates in immunohistochemistry is dif-
ﬁcult, even for pathologists with expertise in the ﬁeld of TB.
Although immunohistochemical staining helps with the
detection of TB/PDC candidates, there is a risk of mis-
classiﬁcation in connection with the common presence of
cytokeratin-positive “competitors”. The assessment of these
objects must be done correctly, on the basis of nuclear
absence. Doubtful (in-)visibility of the cell nucleus in
immunohistochemistry is in this context a complicating
factor that can be remedied with the use of computers.
In this study we have already applied a form of
computer-aided selection by automated preselection based
on color and size. With the results obtained, further steps
can now be taken to achieve automation of TB assessment.
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